Harrow Health Inc is trading 5.0% up now at $37.70, extending its sharp rally from June 10 after the re-launch of its prescriptive VKC eye treatment, VERKAZIA, rekindled investor optimism about its ophthalmology portfolio.
- The stock is also benefiting from a broadly positive tape, with major U.S. indices higher.
- The outsized two-day move versus the market suggests company-specific enthusiasm around VERKAZIA is the primary driver of the current price action.